Andrew Strong, previously general counsel at Texas A&M and now at Kalon Biotherapeutics, talks to Simon Crompton about his new facility, gene patents and employee inventions
Fabrice Mattei of Rouse recommends a patent strategy for biotech and pharma companies in the ASEAN region
Grant Shoebridge and Jacinta Flattery-O’Brien of Shelston IP discuss recent developments that will result in significant changes to the Australian patent system
Kirsten Crain, Beverley Moore and Jennifer Raoul of Borden Ladner Gervais discuss regulatory regimes that interact with and support the patent system in Canada for commercial pharmaceutical and biological products
Ravi Srinivasan and Chris Milton of J A Kemp & Co consider how second medical use claims granted by the European Patent Office may be interpreted during infringement proceedings
Ronney Wiklund and Anette Romare of Valea discuss an apparent trend in the European Patent Office’s assessment of inventive step, in which the objective technical problem is redefined
Archana Shanker of Anand and Anand explains how recent decisions around Section 16 of the Indian Patents Act will change patent applicants’ approach to divisional applications
Alejandro Luna and Juan Luis Serrano Leets of Olivares & Cía look at the main issues set forth by proposed regulations for the approval of biocomparable drugs
The patentability of life sciences innovations in Pakistan has long been an area of confusion. Naeema Sadaf and Saima Sadaf of PakPat provide clarification and looks at other issues concerning patent protection in the industry
Agnieszka Galazka and Marek Lazewski of LDS Lazewski Depo & Partners give advice on obtaining a preliminary injunction in Poland
Mark S Cohen of Pearl Cohen Zedek Latzer discusses the expanding field of personalised medicine, and the patentability of diagnostic claims
Read this year's INTA Daily News - published daily by Managing IP direct from the 134th INTA Annual Meeting in Washington DC
May 2012
Do you want to be famous?
Famous, well-known, notorious, reputed: everyone wants enhanced protection for their trade marks. But should they, and what does it mean if it is? Emma Barraclough explains
Will the new post grant and inter partes review proceedings result in more litigators practising pro hac vice before the USPTO?